-
Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production
•
US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the opening of a 225,000 sq. ft. extension to its manufacturing facility in Durham, North Carolina. The expansion, which has received a USD1 billion investment, will focus on vaccine manufacturing and is a key part of MSD’s ongoing commitment…
-
Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
•
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National Medical Products Administration (NMPA), this time for the treatment of moderate to severe hidradenitis suppurativa (HS). This IL-17A-targeted therapy previously gained approval in China for moderate-to-severe plaque psoriasis, ankylosing spondylitis, and active psoriatic arthritis (PsA).…
-
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting significant revenue growth. In Q4, the company reported revenues of USD187 million, marking a 134.7% year-on-year increase. For the entire year, revenues surged by 120.0% to USD627 million. Carvykti’s Impact on RevenueThe BCMA-directed chimeric antigen…
-
Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera
•
Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to license sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Under the terms of the agreement, Ono has secured global development and commercialization rights to the drug. Terms of the AgreementOno will…
-
Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud
•
German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of Boehringer Ingelheim’s One Medicine Platform, enabled by the implementation of Veeva Development Cloud. This platform aims to streamline end-to-end processes and enhance information sharing across the organization. Strategic PartnershipThe collaboration between BI and Veeva began…
-
Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
•
US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase III trial evaluating the efficacy and safety of its investigational drug felzartamab compared to placebo in adult kidney transplant recipients with late antibody-mediated rejection (AMR). This marks a significant step forward in addressing a critical…
-
MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors
•
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food and Drug Administration (FDA) to initiate a clinical study for its MRANK-106, a dual inhibitor of WEE1 and YES1 kinases. This marks a significant milestone for the company as it expands its innovative oncology pipeline…
-
AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for its serum-free iterative rabies vaccine following the acquisition of the Drug Manufacturing License. The unblinded Phase III study results have demonstrated that the product meets the predetermined evaluation criteria for safety, immunogenicity, and immune persistence.…
-
TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion
•
China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured RMB500 million (USD69 million) in a Series E financing round. The investors include SSF Zhongguancun Independent Innovation Special Fund, Beijing Robotics Industry Development Investment Fund, and Qiming Venture Partners. This funding, the largest primary market…
-
WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259)), has entered into a memorandum of understanding (MOU) with South Korea-based biotech company AbTis. This collaboration aims to enhance innovation in antibody-drug conjugate (ADC) therapeutics and…
-
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical study of its ASC47 in Australia. This adipose-targeted drug candidate, developed in-house, is designed to achieve weight loss without losing muscle mass. Clinical Study ResultsIn the study, ASC47 demonstrated a half-life of up to 26…
-
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
•
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for a new indication for its PD-L1 inhibitor Imfinzi (durvalumab). The approval allows Imfinzi to be used in combination with chemotherapy for adults with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC), specifically for patients without…
-
Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment
•
Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing approval in China for its K-Clip transcatheter tricuspid valve repair system. This approval marks a significant milestone in the treatment of tricuspid regurgitation. Innovation and Market ImpactK-Clip is the first of its kind in China…
-
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
•
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy Officer. Based in the United States, Michael will report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. This strategic move aims to enhance Harbour BioMed’s global influence and business expansion. Role…
-
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
•
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization of HexaBody-CD38 (GEN3014). Consequently, clinical development of the drug will be terminated. The decision was based on…
-
Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the National Medical Products Administration (NMPA) for its sacituzumab tirumotecan (SKB264/MK-2870). The approval allows the use of this TROP2-targeted antibody drug conjugate (ADC) in adult patients with EGFR mutation-positive locally advanced or metastatic non-squamous non-small cell…
-
Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban
•
US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued by China’s Ministry of Commerce (MOFCOM) earlier this year, has responded to the notice from MOFCOM on March 4, 2025. The company faces a prohibition on exporting sequencing instruments into China and has stated its…
-
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to regular approval for Elahere (mirvetuximab soravtansine) has been accepted by the National Medical Products Administration (NMPA). This antibody drug conjugate (ADC) targets folate receptor α (FRα) and represents a significant step forward in the treatment…
-
Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the National Medical Products Administration (NMPA) for its Ameile (almonertinib). The epidermal growth factor receptor (EGFR) inhibitor is now approved to treat unresectable locally advanced EGFR exon 19 deletion or exon 21 (L858R) replacement mutation-positive non-small…
-
IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture
•
China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a joint venture with Aisheng Shourui (HK) Limited. The primary objective of this joint venture is to acquire 85% stakes in South Korea-headquartered REGEN Biotech, Inc. for USD190 million. As part of this transaction, IMEIK will…
